Noteworthy Thursday Option Activity: DKS, OXY, RVMD

Occidental Petroleum options traded 66,513 contracts today (≈6.7 million underlying shares), about 64.5% of OXY's one‑month average daily volume (10.3M), led by 6,252 contracts in the $40 put expiring Jan. 16, 2026 (≈625,200 shares). Revolution Medicines saw 19,134 option contracts (≈1.9M underlying shares), roughly 64% of its one‑month average daily volume (3.0M), led by 2,818 contracts in the $115 call expiring Jan. 16, 2026 (≈281,800 shares). The concentrated strikes and high notional volumes indicate significant positioning or hedging activity that could affect near‑term intraday flows and volatility in OXY and RVMD.

Analysis

Market structure: Large concentrated long-dated OXY put flow (6,252 contracts at $40 Jan‑16‑2026) signals either institutional hedging of sizeable equity exposure or a bearish view on oil/asset-specific downside; this benefits options sellers, diversified commodity hedgers and volatility providers while pressuring levered E&P equity holders if positions are directional. RVMD concentrated long calls ($115 Jan‑16‑2026, 2,818 contracts) points to takeover/trial-success speculation that benefits biotech acquirers and long volatility players and hurts short-biotech momentum players if a positive catalyst materializes.

Risk assessment: Tail risk for OXY includes a sharp oil price collapse (Brent < $65 within 6–12 months) or credit event that could wipe equity value; for RVMD the tail is binary trial failure/M&A walk which could move shares >30% in days. Near term (days–weeks) positioning risk dominates (gamma/liquidity), medium term (months) depends on oil inventories, earnings and trial readouts, long term to Jan‑2026 reflects structural views on energy transition and drug pipeline viability. Hidden dependency: large trades may be flow from structured products or single-account block trades — not pure directional conviction — so IV skew and subsequent unwind can reverse moves rapidly.

Trade implications: If you believe OXY put demand is hedging (not directional), consider selling structured premium (credit spreads) into elevated IV; if you believe RVMD calls are informed, favor asymmetric long exposure (call debit spreads) sized to event risk. Cross-asset: heavy OXY hedging could pressure high-yield E&P bonds and widen CDS, so hedge equity trades with HY protection if size warrants. Monitor IV rank, open interest concentration, Brent spot and scheduled catalysts (OXY earnings, RVMD trial/partnership windows) over next 30–90 days.

Contrarian angle: The market may over-index to single‑strike flow as predictive; historically large concentrated option blocks are often delta-hedge driven and can reverse — e.g., biotech call blocks pre‑M&A rumors that faded. If IV for OXY has already inflated, selling a defined-risk put spread (not naked puts) captures premium with capped downside; conversely if RVMD IV is spiking, prefer spreads over naked calls to avoid IV crush on negative news. Watch for unintended consequences like forced deleveraging in energy funds if oil moves sharply, which can amplify short-term price moves opposite to the block-flow intent.

Key Decisions for Investors

• Sell OXY Jan‑16‑2026 $40/$30 put credit spread sized so max portfolio risk = 0.5%; enter only if OXY 30‑day IV > 20% and collect ≥$1.50 credit per contract; unwind/trim if OXY < $35 for 3 consecutive sessions or Brent < $70 for 10 trading days.
• Establish a bullish RVMD position via Jan‑16‑2026 $90/$115 call debit spread allocating 1–2% of portfolio capital; target 50–100% return or exit if RVMD < $75 for two weeks or a negative Phase/partnership announcement occurs. Enter when RVMD IV rank < 50 to avoid overpaying.
• Run a dollar‑neutral pair: long RVMD Jan‑2026 $90/$115 call spread vs short OXY Jan‑2026 $40/$30 put spread with equal max loss, size combined exposure ≤2% portfolio to express biotech upside vs energy hedging; rebalance monthly and close within 30 days of major catalysts.
• Reduce concentrated exposure to levered E&P (e.g., XOP or individual names with debt/EBITDA < 3x) by 20–30% if OXY 30‑day IV rises >40% from current levels or OXY stock falls >15% in 10 trading days, reallocating proceeds to selective defensive energy infrastructure or cash.